Mutant of L1 Protein of Human Papillomavirus Type 58

    公开(公告)号:US20200268869A1

    公开(公告)日:2020-08-27

    申请号:US15781035

    申请日:2016-12-02

    摘要: Provided are a mutated HPV58 L1 protein or a variant thereof, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein or a variant thereof and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types, and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.

    MUTANT OF L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 18

    公开(公告)号:US20210228703A1

    公开(公告)日:2021-07-29

    申请号:US15734670

    申请日:2019-06-04

    IPC分类号: A61K39/12 C12N7/00

    摘要: The present invention relates to a mutated HPV18 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (for example, HPV18 and HPV45, or HPV18, HPV45 and HPV59), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.

    MUTANT OF L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 51

    公开(公告)号:US20220001002A1

    公开(公告)日:2022-01-06

    申请号:US17280805

    申请日:2019-09-26

    摘要: Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condyloma acuminatum.

    MUTANT OF L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 16

    公开(公告)号:US20210000938A1

    公开(公告)日:2021-01-07

    申请号:US16630673

    申请日:2018-07-13

    IPC分类号: A61K39/12 A61P31/20 A61K39/39

    摘要: Provided are a mutated HPV16 L1 protein (or a variant thereof), a sequence encoding the same and a method for preparing the same, as well as a virus-like particle comprising the same. The protein (or variant thereof) and the virus-like particle are capable of inducing neutralizing antibodies against at least two types of HPV (e.g., HPV16 and HPV35, or HPV16, HPV35, and HPV31), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also provided are a use of the above protein and virus-like particle in the manufacture of a pharmaceutical composition or vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.